Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | PPARD | Q03181 | 4/20 | 0.34 |
| ▸ | PPARA | Q07869 | 4/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17803752 | 0.86 | ACLY (0.34) | SMN1; SMN2KDM4E | |
| SCHEMBL3532124 | 0.81 | CYP3A4 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL29178935 | 0.80 | ESR1 (0.41) | PPARGCYP3A4 | |
| SCHEMBL17803754 | 0.79 | CYP3A4 (0.32) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3535380 | 0.79 | CYP3A4 (0.32) | PPARGPPARDPPARASMYD2CYP3A4 | |
| SCHEMBL30298249 | 0.77 | LOX (0.40) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3923674 | 0.77 | ESR1 (0.33) | CYP3A4 | |
| SCHEMBL17288268 | 0.76 | GAA (0.39) | CYP3A4HTTSMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL6617538 | 0.74 | MAOB (0.49) | PPARGSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3681371 | 0.74 | TRPA1 (0.38) | PPARGPPARDPPARASMYD2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46024-E1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-RE46024-E1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-7807674-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1919878-B1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-20090005383-A1 | THYROID HORMONE ANALOGS | HOFFMANN-LA ROCHE INC. | 2009-01-01 | — | — | US | disclosed |
| US-7452882-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1919878-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. Hoffmann-Roche AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070032494-A1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005383-A1 | THYROID HORMONE ANALOGS | THRA, THRB, TPO | PPARG 29/4885PPARD 54/4885PPARA 43/4885 |
| US-20070032494-A1 | Thyroid hormone analogs | THRA, THRB, TPO | PPARG 29/4885PPARD 54/4885PPARA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.